Insider Selling: Vericel (NASDAQ:VCEL) Director Sells 3,000 Shares of Company Stock

Vericel Corporation (NASDAQ:VCEL) Director Robert Md Zerbe sold 3,000 shares of Vericel stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $52.23, for a total transaction of $156,690.00. Following the sale, the director owned 32,995 shares of the company’s stock, valued at approximately $1,723,328.85. The trade was a 8.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Vericel Trading Up 5.5%

Shares of NASDAQ:VCEL traded up $2.84 during trading on Friday, reaching $54.62. The company had a trading volume of 1,612,332 shares, compared to its average volume of 598,922. The company has a fifty day moving average of $40.74 and a two-hundred day moving average of $38.80. The stock has a market capitalization of $2.80 billion, a P/E ratio of 116.22 and a beta of 1.08. Vericel Corporation has a 12 month low of $28.95 and a 12 month high of $55.60.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.21. Vericel had a net margin of 7.91% and a return on equity of 6.91%. The firm had revenue of $85.37 million for the quarter, compared to analysts’ expectations of $77.95 million. During the same quarter last year, the company posted $0.10 EPS. The business’s quarterly revenue was up 26.5% on a year-over-year basis. As a group, equities research analysts predict that Vericel Corporation will post 0.54 earnings per share for the current year.

Key Vericel News

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Third-quarter revenue rose 26% year over year to $85.4 million, while earnings were $0.27 per share—well above analyst estimates. Net income increased 179% to $14.2 million; the company also cited record MACI sales. Vericel Q3 2026 results and guidance
• Positive Sentiment: Vericel raised its 2026 revenue guidance to $344–$346 million, above the approximately $336 million consensus, and increased its adjusted EBITDA margin guidance to 28%. Vericel Q3 2026 results and guidance
• Positive Sentiment: HC Wainwright raised its price target from $72 to $75 and reaffirmed a Buy rating, signaling continued analyst confidence after the results. HC Wainwright raises Vericel price target
• Negative Sentiment: A separate analysis described VCEL as potentially overvalued relative to its earnings support, a risk if future growth does not justify investor expectations. Analysis of Vericel’s valuation

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of VCEL. GAMMA Investing LLC increased its holdings in shares of Vericel by 17.7% in the second quarter. GAMMA Investing LLC now owns 1,886 shares of the biotechnology company’s stock worth $84,000 after buying an additional 283 shares during the period. Kopp Family Office LLC boosted its holdings in Vericel by 0.6% during the 3rd quarter. Kopp Family Office LLC now owns 51,352 shares of the biotechnology company’s stock valued at $2,061,000 after acquiring an additional 299 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in Vericel by 0.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 157,081 shares of the biotechnology company’s stock valued at $6,195,000 after acquiring an additional 435 shares during the period. Handelsbanken Fonder AB boosted its holdings in Vericel by 2.2% during the 2nd quarter. Handelsbanken Fonder AB now owns 23,079 shares of the biotechnology company’s stock valued at $1,027,000 after acquiring an additional 500 shares during the period. Finally, Gagnon Securities LLC grew its position in Vericel by 7.3% during the 3rd quarter. Gagnon Securities LLC now owns 7,839 shares of the biotechnology company’s stock worth $315,000 after acquiring an additional 536 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on VCEL shares. Truist Financial set a $65.00 price target on Vericel in a research note on Friday. Canaccord Genuity Group set a $60.00 price objective on Vericel in a research report on Thursday, July 30th. TD Cowen increased their price objective on Vericel from $55.00 to $58.00 and gave the company a “buy” rating in a research report on Friday, July 31st. HC Wainwright raised their price objective on Vericel from $72.00 to $75.00 and gave the company a “buy” rating in a report on Friday. Finally, Wall Street Zen upgraded Vericel from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Four investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, Vericel has a consensus rating of “Moderate Buy” and a consensus price target of $60.80.

Vericel Company Profile

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.